NetScientific (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies.
Portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB), in which NSCI holds a 4.72% stake, announced on 3 October that it had completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for its lead candidate, PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrol ....
04 Oct 2022
WH Ireland: NetScientific (NSCI) - PDS Biotech announces positive end-of-phase 2 meeting for lead candidate PDS0101 in combination with KEYTRUDA
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WH Ireland: NetScientific (NSCI) - PDS Biotech announces positive end-of-phase 2 meeting for lead candidate PDS0101 in combination with KEYTRUDA
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
04 Oct 2022 -
Author:
Matthew Davis | Emma Ulker -
Pages:
4
NetScientific (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies.
Portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB), in which NSCI holds a 4.72% stake, announced on 3 October that it had completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for its lead candidate, PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrol ....